Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102405 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101673 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101950 | 0.90 | ALDH1A1 (0.52) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101704 | 0.90 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101631 | 0.88 | ALDH1A1 (0.44) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101958 | 0.88 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101964 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13101640 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13102440 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AHTTMEN1 | |
| SCHEMBL13102472 | 0.85 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663237-B1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7741332-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1663237-A4 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7223768-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1663237-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025293-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885LMNA 1121/4885KMT2A 1295/4885 |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885LMNA 1121/4885KMT2A 1295/4885 |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885LMNA 1121/4885KMT2A 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.